AnaptysBio’s (ANAB) Outperform Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of AnaptysBio (NASDAQ:ANAB) in a research report report published on Monday morning,RTT News reports. The firm currently has a $40.00 price objective on the biotechnology company’s stock. Wedbush also issued estimates for AnaptysBio’s Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.85) EPS, Q3 2025 earnings at ($0.87) EPS, Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($3.05) EPS, FY2026 earnings at ($3.75) EPS, FY2027 earnings at ($4.13) EPS, FY2028 earnings at ($4.77) EPS and FY2029 earnings at ($4.04) EPS.

ANAB has been the topic of a number of other reports. UBS Group upped their target price on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. HC Wainwright cut shares of AnaptysBio from a “buy” rating to a “neutral” rating and cut their price target for the company from $52.00 to $19.00 in a report on Wednesday, December 11th. Truist Financial decreased their price objective on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a report on Wednesday, December 18th. JPMorgan Chase & Co. cut their target price on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a research note on Thursday, December 19th. Finally, Wells Fargo & Company decreased their price target on AnaptysBio from $56.00 to $40.00 and set an “overweight” rating for the company in a research note on Thursday, December 12th. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, AnaptysBio currently has an average rating of “Moderate Buy” and a consensus price target of $40.08.

AnaptysBio Price Performance

Shares of ANAB stock opened at $16.06 on Monday. The company’s fifty day moving average price is $17.05 and its two-hundred day moving average price is $26.77. The firm has a market capitalization of $488.71 million and a P/E ratio of -2.64. AnaptysBio has a 12 month low of $12.51 and a 12 month high of $41.31.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The business had revenue of $30.02 million for the quarter, compared to analysts’ expectations of $7.92 million. On average, sell-side analysts anticipate that AnaptysBio will post -6.08 EPS for the current year.

Insider Transactions at AnaptysBio

In other news, Director Ecor1 Capital, Llc bought 6,646 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was purchased at an average price of $12.95 per share, for a total transaction of $86,065.70. Following the transaction, the director now owns 7,880,094 shares in the company, valued at approximately $102,047,217.30. This trade represents a 0.08 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 33.70% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

Several hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC lifted its stake in shares of AnaptysBio by 15.3% in the 3rd quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company’s stock worth $110,857,000 after acquiring an additional 438,557 shares during the period. Frazier Life Sciences Management L.P. raised its holdings in AnaptysBio by 2.0% during the third quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company’s stock worth $74,008,000 after purchasing an additional 43,598 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in AnaptysBio by 55.1% in the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock worth $15,927,000 after purchasing an additional 168,813 shares during the period. Geode Capital Management LLC boosted its stake in AnaptysBio by 3.0% during the 3rd quarter. Geode Capital Management LLC now owns 465,401 shares of the biotechnology company’s stock valued at $15,594,000 after purchasing an additional 13,336 shares in the last quarter. Finally, Jennison Associates LLC increased its position in shares of AnaptysBio by 1.6% during the 4th quarter. Jennison Associates LLC now owns 269,131 shares of the biotechnology company’s stock valued at $3,563,000 after purchasing an additional 4,242 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.